Identification of 16 novel Alzheimer's disease loci using multi-ancestry meta-analyses.

["Julian Daniel Sunday Willett", "Mohammad Waqas", "Younjung Choi", "Tiffany Ngai", "Kristina Mullin", "Rudolph E Tanzi", "Dmitry Prokopenko"]
Alzheimer's & dementia : the journal of the Alzheimer's Association 2025
Open on PubMed

INTRODUCTION: Alzheimer's disease (AD) is the most prevalent form of dementia. While many AD-associated genetic determinants have been identified, few studies have analyzed individuals of non-European ancestry. METHODS: We conducted a multi-ancestry genome-wide association study (GWAS) of clinically diagnosed AD and AD-by-proxy using whole genome sequencing data from the National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS), National Institute of Mental Health, UK Biobank (UKB), and All of Us (AoU) consisting of 49,149 cases (12,074 clinically diagnosed and 37,075 AD-by-proxy) and 383,225 controls. Nearly half of NIAGADS and AoU participants were of non-European ancestry. RESULTS: For clinically diagnosed AD, we identified 14 new loci-five common (FBN2/SCL27A6, AC090115.1, DYM, KCNG1/AL121785.1, TIAM1) and nine rare (VWA5B1, RNU6-755P/LMX1A, MOB1A, MORC1-AS1, LINC00989, PDE4D, RNU2-49P/CDO1, NEO1, and SLC35G3/AC022916.1). Meta-analysis of UKB and AoU AD-by-proxy cases yielded two new rare loci (RPL23/LASP1 and CEBPA/AC008738.6), also nominally significant in NIAGADS. DISCUSSION: In summary, we provide evidence for 16 novel AD loci and advocate for more studies using whole genome sequencing-based GWAS of diverse cohorts. HIGHLIGHTS: We used whole-genome sequencing data from large and diverse cohorts. We found novel genome-wide association study findings based on whole-genome data. We performed a multiancestry meta-analysis and incorporated results from underrepresented groups.

4 Figures Extracted
FIGURE 1
FIGURE 1 PMC
Study design. AD, Alzheimer's disease; AoU, All of Us; FAVOR, Functional Annotation of Variants Online Resource; HWE, Hardy–Weinberg equilibrium;...
FIGURE 2
FIGURE 2 PMC
Age (A) and sex (B) demographics of individuals representing AD cases compared to controls in each cohort. NIAGADS used clinical AD as a case definiti...
FIGURE 3
FIGURE 3 PMC
Manhattan plots of AD from NIAGADS alone (A) and after meta‐analyzing with NIMH (B). Red genome‐wide significant variants represent variants that pass...
FIGURE 4
FIGURE 4 PMC
Manhattan plot of AD‐by‐proxy meta‐analysis, highlighting variants that were nominally significant ( P  ≤ 0.05) in the NIAGADS–NIMH meta‐analysis. Giv...